AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01268761
Drug: Placebo (saline solution)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: • Placebo (saline solution) 1 ampoule every 24 hours during 7 days beginning administration the second day of oocyte retrieval
Trial: NCT02977533
Drug: GZ402668
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Trial: NCT02977533
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Trial: NCT02540070
Drug: epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02540070
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00432887
Drug: caffeine administration
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03736161
Drug: Group B- Methotrexate
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B patients will receive Methotrexate in increasing dose weekly with maximum dose up to 25 mg/week. Patients will be followed up at 1, 3 and 6 months. Patients with inadequate response to highest dose of MTX at the end of 3 months will be put on Tofacitinib 5 mg BD. Primary endpoint for efficacy will be determined by ACR 20 response.
Trial: NCT02640820
Drug: Sensitizing DPCP Ointment
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensitization
Trial: NCT02640820
Drug: Treatment DPCP Ointment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment
Trial: NCT01322048
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV q6h and Per Tube q12, both for 7 days
Trial: NCT02627989
Drug: Diflucortolone valerate (Nerisona)
RxNorm normalized name: diflucortolone valerate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
Trial: NCT02627989
Drug: Diflucortolone valerate (Texmeten)
RxNorm normalized name: diflucortolone valerate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
Trial: NCT02792153
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AN participants will be prescribed 28 days of transdermal estradiol 0.1 mg/d (Days 1-28) plus 10 days (days 21-31) oral medroxyprogesterone 2.5 mg/d.
Trial: NCT03781505
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal ropivacaine
Trial: NCT03722524
Drug: amlodipine / indapamide / perindopril arginine FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCB / diuretic / ACE inhibitor
Trial: NCT02794519
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.
Trial: NCT02794519
Drug: Rescue medication
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue medication (salbutamol/albuterol) shall be supplied to subjects at Screening for use when needed during the study.
Trial: NCT01679795
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01001923
Drug: Placebo (for REGN475/SAR164877)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes
Trial: NCT04543695
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 6 cycles.~6 courses，3 weeks per course
Trial: NCT04543695
Drug: mFOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of l-LV (400 mg/m2) and oxaliplatin (85 mg/ m2) by intravenous infusion over 2 h, followed by rapid intravenous infusion (iv) of 5-FU (400 mg/m2) and then slow infusion (civ) of 5-FU (2400 mg/m2 over 46 h), is repeated every 2 weeks for 9 cycles.
Trial: NCT02638168
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inert placebo ingredient
Trial: NCT00475904
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo cream and caps
Trial: NCT01090440
Drug: GSK1144814
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study is an open label, randomised, three-way cross-over study to evaluate the pharmacokinetics, effect of food, safety and tolerability of a new tablet formulation of GSK1144814 in healthy male and female (non-child bearing potential) subjects. Sixteen subjects will be enrolled to provide a minimum number of 12 evaluable subjects. The doses to be administered will be 100 mg and 200mg in the fasted state, and 100mg following a high fat breakfast.
Trial: NCT02663830
Drug: clomiphene only
RxNorm normalized name: Clomiphene only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 105 Patients will receive clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
Trial: NCT01529034
Drug: USL261
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03305068
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00142051
Drug: nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 ppm 8 hrs, 40 ppm 8 hrs, 20 ppm 4 hrs, 10 ppm 4 hrs
Trial: NCT01708122
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mcg in 1 mL intranasal spray
Trial: NCT00440804
Drug: ibuprofen l-lysine iv solution (NeoProfen (R) )
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04348032
Drug: PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive PLD and apatinib at the same time. The dose of intravenous chemotherapy drug is calculated according to the body surface area, and the dose of oral drug apatinib is 250mg qd. Dose suspension and dose reduction are allowed only when patients have serious adverse reactions. The intravenous chemotherapy drug PLD dose is only allowed to be down-regulated twice (one time is to reduce the standard dose by 25%), and the oral drug apatinib dose is only allowed to be reduced once (250mg gravity QD changed to 250mg gravity Qod). Otherwise the patients will drop out of the study.
Trial: NCT04348032
Drug: PLD 40mg/m2 ivgtt q4w
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of intravenous chemotherapy drug is calculated according to the body surface area. When patients have serious adverse reactions, dose suspension and dose reduction are allowed. The PLD dose is only allowed to be down-regulated twice (one time is to reduce the standard dose by 25%).
Trial: NCT00479856
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy
Trial: NCT02715167
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00470210
Drug: Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week
Trial: NCT00017628
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01444508
Drug: Ringer-lactate SAD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactated Ringer's is administrated intravenously in the dosis of max. 35 ml/kg during the operation after securing normovolaemia with Nexfin Monitor at induction of the anaesthesia: if bolus infusion of 200 ml increases stroke volume more than 10 % the patient is not assumed normovolaemic and bolus infusions are repeated until normovolaemic status is achieved.
Trial: NCT01631604
Drug: Muscle/nerve injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection to muscle or nerve
Trial: NCT01444508
Drug: HES 130/04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voluven is administered intravenously in the doses of max. 35 ml/kg during the operation. Normovolaemia is achieved in the same way as described in intervention by Ringer-lactate SAD.
Trial: NCT00646581
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02205528
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to NNC0090-2746 will be self-administered daily via SC injection.
Trial: NCT02993029
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib capsule 200mg qd by mouth.
Trial: NCT02205528
Drug: NNC0090-2746
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNC0090-2746 solution will be self-administered in daily doses of 1.8 mg via SC injection.
Trial: NCT01224366
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01796665
Drug: Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01796665
Drug: Placebo of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% product
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01707082
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 0 mg, every 8 hours, 14 days
Trial: NCT02600429
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is composed of the same excipients as RGN-259 but does not contain Tβ4
Trial: NCT01182870
Drug: choleclaciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800-6000 IU cholecalciferol per day
Trial: NCT01707082
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 0 mg, every 8 or 12 hours, 14 days
Trial: NCT03605914
Drug: diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The non-steroidal anti-inflammatory drug (NSAID) used in this study is diclofenac.
Trial: NCT02007252
Drug: ACZ885
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACZ885 150 mg liquid pre-filled syringes were administered s.c..
Trial: NCT02007252
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo liquid pre-filled syringes were administered s.c..
Trial: NCT02206685
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the control group will receive a 20 ml normal saline placebo infusion over 10 minutes
Trial: NCT03299387
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive intravesical via catheter Gentamicin solution 25 mg in 50cc for 3 days
Trial: NCT04296162
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine chemotherapy (oral)
Trial: NCT03393949
Drug: Methylprednisolone 1 mg•kg-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in Group M received methylprednisolone 1mg•kg-1
Trial: NCT03393949
Drug: isotonic saline 1mg•kg-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in Group C received isotonic saline 1mg•kg-1
Trial: NCT01620762
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose every 4 weeks
Trial: NCT00304811
Drug: Vancomycin plus Gentamicin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00304811
Drug: Vancomycin plus Gentamicin plus Rifampin
RxNorm normalized name: betamethasone / clotrimazole / gentamicin Otic Ointment [Vetaderm Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02949271
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03640221
Drug: Hydrochlorothiazide 12.5mg
RxNorm normalized name: HYDROCHLOROTHIAZIDE 12.5MG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparator arm allow us to mimic the mild anti hypertensive effect seen with the SGLT-2 inhibitors in order to enable us to differentiate whether the cardiovascular protection seen with the SGLT-2 inhibitors is secondary to its antihypertensive effects vs the potential decrease in sympathetics.
Trial: NCT00823901
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied placebo gel with no active medication to entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks
Trial: NCT01369511
Drug: LY2495655
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously
Trial: NCT01369511
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously
Trial: NCT00227981
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04322422
Drug: Inhaled corticosteriod/long-acting beta-agonist only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteriod/long-acting beta-agonist are regular inhaled drugs for classic asthma
Trial: NCT01554592
Drug: Withdrawal of statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants currently received statin therapy will have their statin stopped for 12 weeks.
Trial: NCT01554592
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will continue on stable statin therapy.
Trial: NCT01841827
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01257503
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liquid made to look like the active homeopathic remedy
Trial: NCT02256787
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02141347
Drug: MEDI4736
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI4736 administered intravenously.
Trial: NCT03043066
Drug: scaling and root planing along with antibiotic intervention
RxNorm normalized name: dendropanax dentiger root with stem extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects underwent full mouth supragingival and subgingival scaling along with antibiotic intervention of amoxicillin of 500 mg and metronidazole of 400 mg thrice daily for 7 days
Trial: NCT00003311
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003311
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00227747
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00410995
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04454567
Drug: ABI-H0731
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive ABI-H0731 tablets orally once daily
Trial: NCT04454567
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo to ABI-H0731 tablets orally once daily
Trial: NCT04454567
Drug: NrtI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir (ETV), tenofovir alafenamide (TAF), or tenofovir disoproxil fumarate (TDF) SOC according to the respective package insert
Trial: NCT00699335
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl transdermal patch. This was an observational study - therefore, the physician decided about dosage according to individual needs
Trial: NCT01887353
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill manufactured to mimic ranolazine 1000 mg tablets. Patients will be instructed to take two pills a day.
Trial: NCT01939639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intranasal application, sodium chloride solution, 3 puffs per nostril
Trial: NCT02463825
Drug: Placebo (Lactose tablet)
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03952806
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT00710827
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 54 weeks of treatment with placebo, 5 intramuscular injections of 4ml placebo (at baseline, week 6, 18, 30, 42)
Trial: NCT01888835
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01809379
Drug: chemotherapy with doxorubicin and cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intraperitoneal chemotherapy applied as an aerosol and under pressure
Trial: NCT02136420
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04162366
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet, oral use once daily
Trial: NCT01596907
Drug: Ephedrine sulfate with caffeine
RxNorm normalized name: Ephedrine Sulfate
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ephedrine sulfate 25-mg with caffeine 200-mg combination capsule to start 5 weeks after gastric bypass surgery at 3 times per day 4 hours apart.
Trial: NCT01839149
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01456780
Drug: Loteprednol/tobramycin
RxNorm normalized name: LOTEPREDNOL/TOBRAMYCIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zylet (loteprednol/tobramycin) drops, 1 drop twice a day for 4 weeks.
Trial: NCT03548987
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (under the skin) injection of semaglutide placebo once-weekly.
Trial: NCT02195557
Drug: Synvisc®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01885364
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous injection with normal saline before injection of propofol
Trial: NCT01885364
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous injection with remifentanil 0.35 ug/kg before injection of propofol
Trial: NCT02361138
Drug: SHR3824
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02361138
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02886988
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1mlof normal saline will be injected with a 30G needle.
Trial: NCT00621647
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00846391
Drug: MK8245 5 mg (twice a day) b.i.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the 5 mg b.i.d. treatment group took 2 capsules of MK8245 2.5 mg in the morning and 2 capsules of MK8245 2.5 mg in the evening.
Trial: NCT00846391
Drug: MK8245 50 mg b.i.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the 50 mg b.i.d. treatment group took 2 capsules of MK8245 25 mg in the morning and 2 capsules of MK8245 25 mg in the evening.
Trial: NCT00846391
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the placebo treatment group took 2 capsules of placebo matching MK8245 capsules in the morning and 2 placebo capsules matching MK8245 capsules in the evening.
Trial: NCT00361309
Drug: SU011248
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive SU011248 37.5 mg/day for 4 weeks continuously followed by 2 weeks of rest per cycle (each cycle = 6 weeks).
Trial: NCT00820027
Drug: Etoricoxib 90 mg
RxNorm normalized name: etoricoxib 90 MG
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 90 mg tablet once daily
Trial: NCT00820027
Drug: Etoricoxib 120 mg
RxNorm normalized name: etoricoxib 120 MG
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 60 mg tablets once daily
Trial: NCT00820027
Drug: Ibuprofen 600 mg
RxNorm normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One tablet three times daily
Trial: NCT00820027
Drug: Matching Placebo for Etoricoxib 120 mg
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets once daily
Trial: NCT00820027
Drug: Matching Placebo for Etoricoxib 90 mg
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet once daily